Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-05-29
2007-05-29
Saunders, David A. (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S007400, C435S028000, C436S063000, C436S087000
Reexamination Certificate
active
10039753
ABSTRACT:
Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from the general population or a select population of human subjects. Such comparison characterizes the test subject's risk of developing CVD.
REFERENCES:
patent: 5122534 (1992-06-01), Loose et al.
patent: 5731208 (1998-03-01), Heinecke
patent: 5871946 (1999-02-01), Lucas et al.
patent: 5889042 (1999-03-01), MacLean et al.
patent: 5985272 (1999-11-01), Deby et al.
patent: 6096556 (2000-08-01), Heinecke
patent: 6133039 (2000-10-01), Heinecke
patent: 6268220 (2001-07-01), Heinecke
patent: 6953666 (2005-10-01), Kinkade, Jr. et al.
patent: 2003/0119792 (2003-06-01), Roca
patent: 0 389 381 (1990-09-01), None
patent: 02/48715 (2002-06-01), None
patent: 02/50550 (2002-06-01), None
“Oxidized LDL and HDL: antagonists in atherothrombosis” by Mertens, et al.,FASEB J., 15, 2073-2084 (2001).
“Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species” by Podrez, et al.,J. Clin. Ivest. 105:1095-1108 (2000).
“Inhibition of Adhesion Molecules Markedly Ameliorates Cytokine-Induced Sustained Myocardial Dysfunction in Dogs in vivo” by Momii, et al.,J. Mol. Cell. Cardiol. 30, 2637-2650 (1998).
“Supplementation with Tetrahydrobiopterin Suppresses the Development of Hypertension in Spontaneously Hypertension Rats” by Hong, et al.,Hypertension, 2001; 38:1044-1048.
“Myeloperoxidase Deficiency” by Nauseef,Hematology, Oncology Clinics of North America, vol. 2, No. 1, Mar. 1988, pp. 135-158.
“Primary Inherited Defects in Neutrophil Function: Etiology and Treatment” by Malech, et al.,Seminars in Hematology, vol. 34, No. 4, Oct. 1997, pp. 279-290.
“Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall” by Heinecke, et al.,FASEB J., 13, 1113-1120 (1999).
“Myeloperoxidase-Generated Oxidants and Atherosclerosis” by Podrez, et al.,Free Radical Biology&Medicine, vol. 28, No. 12, pp. 1717-1725, Jan. 2000.
“Myeloperoxidase, a Catalyst for Lipoprotein Oxidation, Is Expressed in Human Atherosclerosis Lesions” by Daugherty, et al.,J. Clin. Invest., vol. 94, Jul. 1994, 437-444.
“3-Chlorotyrosine, a Specific Marker of Myeloperoxidase-catalyzed Oxidation, Is Markedly Elevated in Low Density Lipoprotein Isolated from Human Atherosclerosis Intima” by Hazen, et al.,J. Clin. Invest., vol. 99, No. 9, May 1997, 2075-2081.
Elevated levels of protein-boundp-hydroxyphenylacetaldehyde, an amino acid-derived aldehyde generated by myeloperoxidase, are present in hun fatty streaks, intermediate lesions and advanced atherosclerosis lesions by Hazen, et al.,Biochem J. (2000) 352, 693-699.
“p-Hydroxypheylacetaldehyde, an Aldehyde Generated by Myeloperoxidase, Modifies Phospholipid Amino Groups of Low Density Lipoprotein in Human Atherosclerosis Intima” by Heller, et al.,The Journal of Biological Chemistry, vol. 275, No. 14, Apr. 7, 2000, pp. 9957-9962.
“Association Between Myeloperoxidase Levels and Risk of Coronary Artery Disease” by Zhang, et al.,JAMA, vol. 286, No. 17, Nov. 7, 2001, pp. 2136-2142.
“Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis? Do the Antioxidant Trials Conducted to Date Refute the Hypothesis?” by Steinberg, et al.,Circulation, 2002; 105:2107-2111.
“Kinetics of Oxidation of Tyrosine and Dityrosine by Myeloperoxidase Compounds I and II” by Marquez, et al.,The Journal of Biological Chemistry, vol. 270, No. 51, Dec. 22, 1995, pp. 30434-30440.
“Leukocytes Utilize Myeloperoxidase-Generated Nitrating Intermediates as Physiological Catalysts for the Generation of Biologically Active Oxidized Lipids and Sterols in Serum” by Schmitt, et al.,Biochemistry, 1999, 38, 16904-16915.
“Nitric Oxide Modulates the Catalytic Activity of Myeloperoxidase” by Abu-Soud, et al.,The Journal of Biological Chemistry, vol. 275, No. 8, Feb. 25, 2000, pp. 5425-5430.
“Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels” by Downs, et al.,JAMA, May 27, 1998, vol. 279, No. 20, pp. 1615-1622.
“The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels” by Sacks, et al.,The New England Journal of Medicine, vol. 335, No. 14, Oct. 3, 1996, pp. 1001-1009.
“Byeond Cholesterol: Modifications of Low-Density Lipoprotein that Increase its Atherogenecity” by Steinberg, et al.,The New England Journal of Medicine, vol. 320, No. 14, Apr. 6, 1989, pp. 915-924.
“Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors” by Takemoto, et al.,Arterioscler Throm Vasc Biol, 2001;21:1712-1719.
“The Evolving Role of Statins in the Management of Atherosclerosis” by Vaughan, et al.,Journal of the American College of Cardiology, vol. 35, No. 1, 2000, pp. 1-10.
“Reduction of Plasma 24S-Hydroxycholesterol (Cerebrosterol) Levels Using High-Dosage Simvastatin in Patients with Hypercholesterolemia” by Locatelli, et al.,Arch Neurol, vol. 59, Feb. 2002, pp. 213-216.
“Alzehimer's Disease: Bad for the Heart, Bad for the Mind” by Marx,Science, vol. 294, Oct. 19, 2001, pp. 508-509.
3-Hydroxy-3-methylglutaryl-coenzyme A reductase in mRNA in Alzheimer and control brain by Yasojima, et al.,Clinical Neuroscience and Neuropathology, vol. 12, No. 13, Sep. 17, 2001, pp. 2935-2938.
“Lovastatin Treatment Decreases Mononuclear Cell Infiltration Into the CNS of Lewis Rats with Experimental Allergic Encephalomyelitis” by Stanislaus, et al.,Journal of Neuroscience Research, 66:155-162 (2001).
“Effect of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors on the Progression of Calcific Aortic Stenosis” by Novaro, et al.,Circulation, 2001; 104:2205-2209.
“Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events” by Ridker, et al.,The New England Journal of Medicine, vol. 344, No. 26, Jun. 28, 2001, pp. 1959-1965.
“Rapid Reduction in C-Reactive Protein with Cerivastatin Among 785 Patients with Primary Hypercholesterolemia” by Ridker,Circulation, 2001; 103:1191-1193.
“Are Statins Anti-Inflammatory? Issues in the Design and Conduct of the Pravastatin Inflammation C-Reactive Proetin Evaluation” by Ridker, et al.,Current Cardiology Reports, 2000, 2:269-273.
“Circulating Myeloperoxidase and Anti-Myeloperoxidase Antibody in Patients with Vasculitis” by Monota, et al.,Scand J. Rheumatol, 1999;25:94-9.
Hazen Stanley
Zhang Renliang
Calfee Halter & Griswold
Saunders David A.
The Cleveland Clinic Foundation
LandOfFree
Myeloperoxidase, a risk indicator for cardiovascular disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Myeloperoxidase, a risk indicator for cardiovascular disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Myeloperoxidase, a risk indicator for cardiovascular disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3764987